Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations

Department of Psychiatry and Psychotherapy, University Medical Center, Freiburg, Germany.
International Journal of Impotence Research (Impact Factor: 1.76). 10/2005; 18(3):229-35. DOI: 10.1038/sj.ijir.3901395
Source: PubMed


This meta-analytic study aims to estimate the likely improvements of erectile dysfunction (ED) measured by the International Index of Erectile Function (IIEF) at the highest fixed dosages of the three available PDE-5-inhibitors: sildenafil, tadalafil, and vardenafil. MEDLINE and the Cochrane Library were searched electronically for efficacy trials of PDE-5-inhibitors for treating ED. In addition drug manufacturers were contacted to provide unpublished or unrecorded congress proceedings. Randomized, double-blind, placebo-controlled, parallel-group, maximum fixed-dose, broad-spectrum efficacy trials using IIEF were included in the analysis. Data were independently extracted by two reviewers. The results were pooled using weighted mean differences. A formal indirect comparison (including Bonferroni-correction) was conducted to estimate the differences between agents. A total of 14 trials were included in the meta-analysis (three with 100 mg sildenafil, eight with 20-25 mg tadalafil, and three with 20 mg vardenafil). All trials were of good methodological quality. Overall heterogeneity was moderate: I(2)=33.2%, chi(2)=19.47, P=0.11. The funnel plot suggested moderate likelihood of publication bias. Pooled results of IIEF-improvement were for sildenafil 9.65 (95% CI: 8.50, 10.79) points, tadalafil 8.52 (7.61, 9.42) points, and vardenafil 7.50 (6.50, 8.50) points, respectively. Sildenafil proved to be significantly more effective than vardenafil (d=2.15, P=0.006), other pairwise comparisons showed no difference in efficacy. All PDE-5-inhibitors are highly effective in the treatment of ED. At maximum dosage they improve erectile function 7-10 points on the IIEF compared to placebo-treatment. There is evidence that sildenafil might be more efficacious than vardenafil, although this is to be interpreted with caution. To prove higher efficacy truly independent comparative trials are needed.

Download full-text


Available from: Levente Kriston, Sep 28, 2014
135 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Medical therapy is the preferred first-line approach in the management of lower urinary tract symptoms in men with benign prostatic hyperplasia. The magnitude of the improvement in lower urinary tract symptoms observed in response to combination therapy (alpha-blocker plus 5-alpha reductase inhibitors) does not approach that achieved with prostatectomy. Various drugs have been under consideration, including BXL628, lonidamine, and phosphodiesterase inhibitors, all of which have had unacceptable side effects. The gonadotropin-releasing hormone antagonist cetrorelix is associated with dose-dependent symptom improvement and reduction of prostate volume. Elucidating the mechanism for cetrorelix-mediated improvement in lower urinary tract symptoms will likely contribute to unraveling the pathophysiology of lower urinary tract symptoms in men.
    Reviews in urology 02/2006; 8(4):183-9.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several trials and reviews provide evidence for the efficacy of phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction (ED). However, little is known about the impact of treatment effect modifiers other than concomitant diseases. Our objective was to identify patient and trial characteristics as well as methodological and publication-related issues that are associated with the treatment effect measured in flexible-dose randomized controlled trials of oral sildenafil for ED. The MEDLINE and the Cochrane Central databases were searched for efficacy trials of sildenafil. Thirteen trials fulfilled all inclusion criteria. A series of meta-regression and graphical analyses were performed to test the impact of possible effect modifiers. Treatment effect was influenced by mean baseline disease severity and mean duration of the disease. These associations were at least partly mediated by placebo response. Trial duration, age of patients and etiology of ED in patients did not have any significant influence on the treatment effect. The year of publication of primary trials was also related to trial findings. Our analysis adds important data to enable the control of confounding variables in future trials and meta-analyses. It might also help the individual to assess the unbiased efficacy and true innovative potential of available and forthcoming pharmacological agents.
    International Journal of Impotence Research 05/2006; 18(6):559-65. DOI:10.1038/sj.ijir.3901479 · 1.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sexual activity remains important for most men throughout their adult lives and into old age; erectile dysfunction (ED) usually leads to a worsening of their sexual experience and can cause significant personal and interpersonal distress at any age. The availability of effective and well-tolerated oral therapy with phosphodiesterase type 5 (PDE5) inhibitors allows most men with ED to once again experience better sex. The concept of better sex is important to men and involves several factors: Enhanced penile rigidity is one factor most frequently desired by affected men. Other factors may be vital to a satisfactory treatment outcome, but enhanced rigidity is frequently seen by affected men as the foundation upon which better sex is based. Loss of penile rigidity can have a profoundly adverse effect on a man's psychological well-being and may be associated with behavioural changes such as the avoidance of intimacy that can impair not only their response to therapy, but also their general relationship with their partner. Successful treatment of ED improves a man's self-confidence and self-esteem; however, since many men delay seeking professional help, relationship problems may be well established by the time they receive treatment. Prolonged abstinence as a consequence of ED may also affect the partners’ sexuality, both in terms of desire and responsiveness. To achieve better sex, any treatment plan for ED must take into account the broader context of a man's sexual experience, including behavioural, relationship, and partner factors.
    European Urology Supplements 09/2006; 5(13):761-766. DOI:10.1016/j.eursup.2006.06.003 · 3.37 Impact Factor
Show more